KAS
ABCL icon

Kestra Advisory Services’s AbCellera Biologics ABCL Stock Holding History

Kestra Advisory Services’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-13,818
Closed -$35.9K – 2649
2024
Q3 		$35.9K Buy
13,818
+3,000
+28% +$8.31K ﹤0.01% 2514
2024
Q2 		$32K Buy
+10,818
New +$40.9K ﹤0.01% 2574

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Kestra Advisory Services's ABCL Position: Q4 2024 in Review

Kestra Advisory Services sold out of AbCellera Biologics (ABCL) in Q4 2024, closing a stake of 13,818 shares — an estimated $35.9K sold.

Kestra Advisory Services first reported a position in ABCL in Q2 2024 and held it in 2 quarters. The position peaked at $35.9K in Q3 2024. 146 funds tracked by Wall St. Rank hold ABCL as of Q4 2024.

  • Kestra Advisory Services reported no remaining AbCellera Biologics position as of Q4 2024 after selling out during the quarter.
  • Kestra Advisory Services sold 13,818 AbCellera Biologics shares in Q4 2024, an estimated $35.9K.
  • Kestra Advisory Services first reported a position in AbCellera Biologics in Q2 2024 and held it in 2 quarters.
  • Kestra Advisory Services's AbCellera Biologics position peaked at $35.9K in Q3 2024.
  • 146 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2024.

Based on Kestra Advisory Services's 13F filing for Q4 2024, filed 10 Feb 2025.